Onward medical announces first-in-human use of arc-im lumbar lead designed to restore standing, stepping, and lower limb mobility

The arc-im lumbar lead is the second model in the arc-im lead family to be used in a clinical feasibility study the company is building a portfolio of purpose-designed leads to optimize delivery of arc-im therapy at various locations along the spinal cord to enable restoration of movement and other functions eindhoven, the netherlands, march 26, 2025 (globe newswire) -- onward medical n.v. (euronext: onwd), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (sci) and other movement disabilities, today announces the first human implant of its investigational arc-im® lumbar lead.
ARC Ratings Summary
ARC Quant Ranking